Genomic Testing and Targeted therapy in Breast Cancer: 2023 Review and Renew Lake Tahoe
Dr Naomi Dempsey MD, from Miami Cancer Institute comments on the growing availability of targeted therapies, and a corresponding need for NGS and genetic testing in advanced breast cancer: Elacestrant, an oral SERD for ESR1 mutation, alpelisib with endocrine therapy for PIK3CA mutation, the AKT inhibitor capivasertib, and other options following progression on CDK4/6 inhibitors.
Related Resources